Current Search: Copik, Alicja (x)
View All Items
- Title
- ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS FOR CANCER IMMUNOTHERAPY WITH EX21 EXOSOMES.
- Creator
-
Khederzadeh, Sara, Copik, Alicja, University of Central Florida
- Abstract / Description
-
In the field of cancer immunotherapy, NK cells are recognized for their ability to provide a form of innate immunity against tumor cells. However, the average abundance of NK cells in the blood can be as low as 5% of the total lymphocyte population. As a result, it has been a focus to find novel therapies to expand NK cells in vitro while subsequently enhancing the cytotoxicity of these cells. Previously-defined methods include the minimal expansion of NK cells with high levels of cytokines...
Show moreIn the field of cancer immunotherapy, NK cells are recognized for their ability to provide a form of innate immunity against tumor cells. However, the average abundance of NK cells in the blood can be as low as 5% of the total lymphocyte population. As a result, it has been a focus to find novel therapies to expand NK cells in vitro while subsequently enhancing the cytotoxicity of these cells. Previously-defined methods include the minimal expansion of NK cells with high levels of cytokines such as IL-2 and IL-15, as well as co-culturing NK cells with feeder cell populations that are genetically modified to express NK-stimulating factors. Another method involves the use of artificially-derived plasma membrane nanoparticles (PM21) that express membrane-bound IL-21 (mb21) to successfully expand NK cells by a factor of 103 in 14 days. Exosomes, which are cell-derived vesicles naturally secreted by cancer cells, may reveal a novel way to expand NK cells and enhance their cytotoxicity by taking advantage of the exchange of genetic information within the tumor microenvironment. To test this hypothesis, NK cells have been cultured with varying concentrations of exosomes derived from modified K562-mb21-41BBl (a chronic myelogenous leukemia cell line) and shown to achieve 200-fold expansion of NK cells from other PBMCs in 14 days, a growth comparable to that of PM-21 particles. In vitro assays as well as co-culturing with various tumor cell lines will determine the cytotoxicity of these expanded cells. Potentially, exosomes may be applied as an in vivo therapy for NK cell expansion.
Show less - Date Issued
- 2017
- Identifier
- CFH2000262, ucf:45963
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFH2000262
- Title
- THE EFFECT OF K562-IL21-2 PLASMA MEMBRANE PARTICLES ON THE PROLIFERATION OF NATURAL KILLER CELLS TO FIGHT CANCER.
- Creator
-
Prophete, Michelle, Copik, Alicja, University of Central Florida
- Abstract / Description
-
Immunotherapy has emerged as a current and future paradigm of cancer treatment, which utilizes the body's immune system to eradicate cancer. Natural Killer (NK) cells as part of the innate immune system have immense potential in their anti-tumor cytotoxic activities and host cell surveillance properties. NK cells comprise approximately five to fifteen percent of peripheral blood lymphocytes and can be proliferated in vitro using recently developed methods with co-cultures with feeder cells ...
Show moreImmunotherapy has emerged as a current and future paradigm of cancer treatment, which utilizes the body's immune system to eradicate cancer. Natural Killer (NK) cells as part of the innate immune system have immense potential in their anti-tumor cytotoxic activities and host cell surveillance properties. NK cells comprise approximately five to fifteen percent of peripheral blood lymphocytes and can be proliferated in vitro using recently developed methods with co-cultures with feeder cells (derived from engineered tumor cells) or plasma membrane (PM) particles, produced from the fore mentioned feeder cells, in combination with soluble cytokines. For efficient growth and maintenance of these NK cells, Interleukin-2 (IL-2) is utilized. IL-2 in solution, through receptor mediated signaling, stimulates proliferation of T-cells and NK cells. NK cells have lower responsiveness to IL-2 and consequently require a larger systemic dose to stimulate them as opposed to competing cell populations that have higher expression of receptors for IL-2, such as T-cells, which can have the effect of lower effective stimulation of NK cell growth. Such difference in the stimulatory capability of IL-2 toward NK cells and the short circulation lifetime of soluble IL-2 require higher dosages of soluble IL-2 for effective in vivo NK cell proliferation for therapeutic application against cancer, but is toxic. Therefore establishing another form of IL-2 delivery that improves its specific targeting to NK cells would be beneficial and may be crucial for novel therapeutic improvement. The Copik Laboratory has made an IL-2 fusion protein construct having a membrane anchor for expression of membrane-bound IL-2 on K562-41bbl-21 cells (K562-IL21). K562-IL21 cells are selectively recognized by NK cells and stimulate their proliferation and cytotoxicity. Hence, a K562-IL21 membrane-bound IL-2 form should be targeted to NK cells with IL-2 delivery. K562-IL21-2 cells were then used to prepare PM21-2 particles which have the potential to provide NK cell targeted, long-lived form of IL-2 for use as an injectable drug for in vivo adjuvant stimulation of NK cells. The presence of IL-2 on the in the PM21-2 particle product was verified by Western blot, and ELISA. Particle preparations from the modified K562 cells should possess characteristics that allow them to possibly replace soluble IL-2 and more specifically increase the numbers or anti-tumor activity of NK cell populations. The effect of PM21-2 particles was studied in in vitro culture based experiments, which tested the effectiveness the PM21-2 particles to induce selective NK cells expansion as compared to PM21 particles in the presence or absence of soluble IL-2.
Show less - Date Issued
- 2017
- Identifier
- CFH2000353, ucf:45918
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFH2000353
- Title
- DEVELOPMENT OF METHODS TO MODULATE NATURAL KILLER CELLS.
- Creator
-
Shaver, Kari A, Copik, Alicja, University of Central Florida
- Abstract / Description
-
Natural Killer (NK) cell based immunotherapies have demonstrated success against malignancies and hematological cancers. However, tumors have developed mechanisms to evade detection by and suppress the immune system, commonly through altering the expression of cell-surface proteins. Overexpression of human leukocyte antigen-E (HLA-E), which binds to the inhibitory NKG2A on NK cells, protects malignant cells from lysis. Downregulating the NKG2A receptor on NK cells should release NK cell...
Show moreNatural Killer (NK) cell based immunotherapies have demonstrated success against malignancies and hematological cancers. However, tumors have developed mechanisms to evade detection by and suppress the immune system, commonly through altering the expression of cell-surface proteins. Overexpression of human leukocyte antigen-E (HLA-E), which binds to the inhibitory NKG2A on NK cells, protects malignant cells from lysis. Downregulating the NKG2A receptor on NK cells should release NK cell inhibition, but proves challenging as NK cells are difficult to transfect and no good methods currently exist. This project is designed to investigate the use of exosomes - small vesicles and natural carriers of regulatory microRNAs (miRNAs) and proteins that are shed from cells - as delivery vehicles for small RNAs (sRNAs) to immune cells. Exosomes are biologically compatible, immunologically inert, and interact with target cells through receptor-ligand interactions, allowing for targeted delivery of cargo. Exosomes loaded with shRNA against NKG2A were cultured in vitro with NK cells. Delivery success was assessed by monitoring NKG2A receptor expression on NK cells through flow cytometry. This research will provide valuable information that will likely impact the delivery of RNA therapeutics and unlock the full cytotoxic potential of NK immunotherapy.
Show less - Date Issued
- 2018
- Identifier
- CFH2000455, ucf:45720
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFH2000455
- Title
- Determining differential effects of Interleukin-2 on innate and adaptive immune cells in lymphoid organs and the gastrointestinal Tract.
- Creator
-
Singh, Ayushi, McKinstry, Karl, Naser, Saleh, Copik, Alicja, University of Central Florida
- Abstract / Description
-
Interleukin-2 (IL-2) is a pleiotropic cytokine demonstrated to be effective in treating cancer. However, the clinical use of IL-2 can be associated with severe side effects including gastrointestinal toxicity (GT). Similar GT symptoms are observed in inflammatory diseases such as CD (CD). Interestingly mounting evidence indicates a role for IL-2 in CD, but the underlying mechanisms are unknown. Indeed, studies on the in-vivo activities of IL-2 have mostly focused on secondary lymphoid organs...
Show moreInterleukin-2 (IL-2) is a pleiotropic cytokine demonstrated to be effective in treating cancer. However, the clinical use of IL-2 can be associated with severe side effects including gastrointestinal toxicity (GT). Similar GT symptoms are observed in inflammatory diseases such as CD (CD). Interestingly mounting evidence indicates a role for IL-2 in CD, but the underlying mechanisms are unknown. Indeed, studies on the in-vivo activities of IL-2 have mostly focused on secondary lymphoid organs and immune cells associated with them. Very few studies have addressed how IL-2 signals impact populations of immune cells in the gut. Here, we aim to identify and compare the effects of systemic IL-2 administration on six major leukocyte population and their subsets in mice using multicolor flow cytometry. While we confirmed previously observed changes in specific immune cell populations in the spleen, very few changes were seen in the gut and gut associated lymphoid tissues. Unexpectedly, a sharp decline was seen in B cells, most notably in Peyer's Patches, in mice treated with IL-2. Our data furthermore indicates that B cells in IL-2 treated mice undergo enhanced apoptosis in Peyer's Patches. Some studies suggest that changes in B cells may contribute to development of CD. Thus, this study may aid in defining ways in which IL-2 can contribute to disease etiology, and lead to novel treatments for CD.
Show less - Date Issued
- 2019
- Identifier
- CFE0007865, ucf:52777
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFE0007865
- Title
- A Cytoplasmic-Replicating RNA Virus Sensitizes Cancer Cells to DNA Modifying Agents.
- Creator
-
Fox, Candace, Parks, Griffith, Copik, Alicja, Khaled, Annette, Zervos, Antonis, University of Central Florida
- Abstract / Description
-
The Parainfluenza virus 5 (PIV5) mutant P/V-CPI- is restricted for spread in normal cells but not in cancer cells in vitro and is effective at reducing tumor burden in mouse model systems. Here we show that P/V-CPI- infection of human laryngeal cancer HEp-2 cells resulted in the majority of the cells dying, but unexpectedly, a population of cells emerged as P/V-CPI- persistently infected (PI) cells. P/V-CPI- PI cells had elevated levels of basal caspase activation, and viability was highly...
Show moreThe Parainfluenza virus 5 (PIV5) mutant P/V-CPI- is restricted for spread in normal cells but not in cancer cells in vitro and is effective at reducing tumor burden in mouse model systems. Here we show that P/V-CPI- infection of human laryngeal cancer HEp-2 cells resulted in the majority of the cells dying, but unexpectedly, a population of cells emerged as P/V-CPI- persistently infected (PI) cells. P/V-CPI- PI cells had elevated levels of basal caspase activation, and viability was highly dependent on activity of cellular inhibitors of apoptosis, such as Survivin. In challenge experiments with external inducers of apoptosis, the PI cells were highly sensitive to cisplatin-induced DNA damage and cell death. This increased cisplatin sensitivity correlated with defects in the phosphorylation cascade controlling DNA damage signaling pathways, as well as translocation of damage-specific DNA binding protein 1 (DDB1) to the nucleus. Similar sensitivity to cisplatin was seen with cells during acute infection with P/V-CPI-, as well as acute infections with WT PIV5. Based on this finding, we tested the hypothesis that histone deacetylase (HDAC) inhibitors would also act with P/V-CPI- infection to enhance cancer cell killing. Using human lung and laryngeal cancer cell lines, 10 HDAC inhibitors were tested for their effect on viability of P/V-CPI- infected cells. HDAC inhibitors such as scriptaid enhanced caspase-3/7, -8 and -9 activity induced by P/V-CPI- and overall cell toxicity. Scriptaid treatment also enhanced the spread of P/V-CPI- through a population of cancer cells and suppressed interferon-beta induction through blocking phosphorylation and nuclear translocation of Interferon Regulatory Factor 3 (IRF-3). These results support a therapeutic approach of combining parainfluenza infection and chemotherapy, but also raise questions on the mechanism by which a cytoplasmic-replicating RNA virus can alter cellular DNA damage responses.
Show less - Date Issued
- 2019
- Identifier
- CFE0007803, ucf:52355
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFE0007803
- Title
- Novel Cytokine Signaling and Molecular Therapeutic Strategy in Pancreatic Cancer.
- Creator
-
Gitto, Sarah, Altomare, Deborah, Khaled, Annette, Zhao, Jihe, Copik, Alicja, Masternak, Michal, University of Central Florida
- Abstract / Description
-
Pancreatic ductal adenocarcinoma (PDAC) is highly chemo-resistant and has a five year survival rate of (
Show morePancreatic ductal adenocarcinoma (PDAC) is highly chemo-resistant and has a five year survival rate of (<)8%. Risk factors of pancreatic cancer, such as chronic pancreatitis, help to elicit a pro-tumor immune response, and highly fibrotic environment that promotes tumorigenesis. To study how chronic pancreatitis promotes cancer initiation, traditional KRasG12D mice and double mutant Akt1Myr/KrasG12D mice were used to model microenvironment changes. Akt1Myr/KrasG12D mice were more susceptible to chronic tissue damage, accelerated tumor development and metastatic disease. These mice exhibited histological changes consistent with immune cell privilege, where M2 macrophages and non-cytotoxic eosinophils were co-localized with fibrotic regions. IL-5 expression was up regulated in pancreatic cells undergoing acinar to ductal metaplasia and then diminished in advanced lesions. Tumor cells treated with IL-5 exhibit increased migration and activation through STAT5 signaling. Collectively, the results suggest that eosinophils, which are responsive to IL-5, are key mediators in the pancreatic environment subjected to chronic inflammation and injury.Current therapeutics fall short in increasing patient survival. There remains an urgent need for innovative treatments and thus we tested difluoromethylornithine (DFMO) in combination with a novel polyamine transport inhibitor, Trimer44NMe, against Gemcitabine-resistant PDAC cells. Prior clinical failures when targeting polyamine biosynthesis with DFMO monotherapy may be due to tumor escape via an undefined polyamine transport system. In pancreatic tumor cells DFMO alone and with Trimer44NMe significantly reduced PDAC cell viability by inducing apoptosis or cell cycle arrest. In vivo orthotopic PDAC growth with DFMO treatment resulted in decreased c-Myc expression, a readout of polyamine pathway dysfunction. Moreover, dual inhibition significantly prolonged survival of tumor-bearing mice, and increased M1 macrophage infiltration and reduced FoxP3 expression. Collectively, these studies demonstrate that targeting polyamine pathways in PDAC is a promising immunomodulating therapy that increases survival.
Show less - Date Issued
- 2017
- Identifier
- CFE0007283, ucf:52168
- Format
- Document (PDF)
- PURL
- http://purl.flvc.org/ucf/fd/CFE0007283